2015
Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma
Bhatt V, Scordo M, Hsu M, Omuro A, DeAngelis L, Lin A, Matasar M, Dahi P, Moskowitz C, Giralt S, Sauter C. Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma. Blood 2015, 126: 1994. DOI: 10.1182/blood.v126.23.1994.1994.Peer-Reviewed Original ResearchHDT-ASCTIdeal body weightComplete remissionPartial remissionBody weightBusulfan/cyclophosphamide conditioningAutologous stem cell transplantationSecondary CNS lymphomaTransplant related mortalityHigh-dose therapyStem cell infusionStem cell transplantationBU AUCCyclophosphamide conditioningHCT-CIChemosensitive patientsFirst remissionPrior therapyRemission inductionCNS lymphomaFirst doseTarget AUCCell infusionMedian ageDosage adjustment
2010
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
Omuro A, Taillandier L, Chinot O, Sierra del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K, On behalf of the ANOCEF Group (French Neuro-Oncology Association).. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Journal Of Neuro-Oncology 2010, 104: 323-330. PMID: 21170569, DOI: 10.1007/s11060-010-0497-x.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyHigh-dose chemotherapyProgression-free survivalPrimary central nervous system lymphomaSalvage whole brain radiotherapyComplete responseOverall survivalNeurotoxicity riskMedian progression-free survivalCentral nervous system lymphomaAdditional chemotherapy cyclesEffective salvage treatmentMedian overall survivalStem cell rescuePrimary CNS lymphomaNervous system lymphomaObjective of treatmentChemosensitive diseaseChemosensitive patientsChemotherapy cyclesInduction chemotherapyBrain radiotherapyCNS lymphomaObjective responseSalvage treatment
2006
Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred?
Omuro A, Taillandier L, Chinot O, Carnin C, Barrie M, Soussain C, Leblond V, Hoang-Xuan K. Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred? Journal Of Clinical Oncology 2006, 24: 1551-1551. DOI: 10.1200/jco.2006.24.18_suppl.1551.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaHigh-dose chemotherapyProgression-free survivalMedian progression-free survivalOverall survivalComplete responseMaintenance chemotherapySalvage treatmentDay 1Central nervous system lymphomaAcceptable initial approachEffective salvage treatmentGrade 3/4 hematotoxicityMedian overall survivalStem cell rescueFurther treatmentNervous system lymphomaRole of RTIT chemotherapyMedian KPSYounger ptsChemosensitive patientsInduction chemotherapyToxic deathsMedian age